REDUCTION OF LDL CHOLESTEROL BY PRAVASTATIN DOES NOT INFLUENCE PLATELET ACTIVATION IN PATIENTS WITH MILD HYPERCHOLESTEROLEMIA AT RISK OF CORONARY HEART-DISEASE

被引：17

作者：

BARROW, SE ^{[1
]}

STRATTON, PD ^{[1
]}

BENJAMIN, N ^{[1
]}

BRASSFIELD, T ^{[1
]}

RITTER, JM ^{[1
]}

机构：

[1] BRISTOL MYERS SQUIBB PHARMACEUT,CLIN RES DEPT,HOUNSLOW TW3 3JA,MIDDX,ENGLAND

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1991年 / 32卷 / 01期

关键词：

THROMBOXANE A2; PLATELET ACTIVATION; PRAVASTATIN; LDL; HYPERCHOLESTEROLEMIA;

D O I：

10.1111/j.1365-2125.1991.tb05625.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The effect of pravastatin on low density lipoprotein (LDL) cholesterol and platelet activation was studied in 16 patients with mild hypercholesterolaemia who had two or more additional cardiovascular risk factors. Patients were treated with either pravastatin (20-40 mg day-1) or placebo for 1 year. Plasma LDL and urinary excretion of 2,3-dinor-thromboxane B2 (an index of platelet activation in vivo) were determined at 0, 3, 6 and 12 months. There was a significant reduction in LDL at 6 and 12 months (2P < 0.05) but this was not associated with any significant change in thromboxane metabolite excretion.

引用

页码：127 / 129

页数：3

共 14 条

[1] PLATELET ACTIVATION BY PLASMA-LIPOPROTEINS [J].

AVIRAM, M ;

BROOK, JG .

PROGRESS IN CARDIOVASCULAR DISEASES, 1987, 30 (01) :61-72

[2] CIGARETTE-SMOKING - PROFILES OF THROMBOXANE-DERIVED AND PROSTACYCLIN-DERIVED PRODUCTS IN HUMAN-URINE [J].

BARROW, SE ;

WARD, PS ;

SLEIGHTHOLM, MA ;

RITTER, JM ;

DOLLERY, CT .

BIOCHIMICA ET BIOPHYSICA ACTA, 1989, 993 (01) :121-127

[3] MEVINOLIN AND COLESTIPOL STIMULATE RECEPTOR-MEDIATED CLEARANCE OF LOW-DENSITY LIPOPROTEIN FROM PLASMA IN FAMILIAL HYPERCHOLESTEROLEMIA HETEROZYGOTES [J].

BILHEIMER, DW ;

GRUNDY, SM ;

BROWN, MS ;

GOLDSTEIN, JL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (13) :4124-4128

[4] PLATELET-FUNCTION AND LIPOPROTEIN LEVELS AFTER PLASMA-EXCHANGE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA [J].

BROOK, G ;

WINTERSTEIN, G ;

AVIRAM, M .

CLINICAL SCIENCE, 1983, 64 (06) :637-642

[5] CLOFIBRATE REVERSAL OF PLATELET HYPERSENSITIVITY IN HYPERBETALIPOPROTEINEMIA [J].

CARVALHO, AC ;

COLMAN, RW ;

LEES, RS .

CIRCULATION, 1974, 50 (03) :570-574

[6] MEASUREMENT OF RENAL AND NONRENAL EICOSANOID SYNTHESIS [J].

CATELLA, F ;

NOWAK, J ;

FITZGERALD, GA .

AMERICAN JOURNAL OF MEDICINE, 1986, 81 (2B) :23-29

[7] PAIRED ANALYSIS OF URINARY THROMBOXANE-B2 METABOLITES IN HUMANS [J].

CATELLA, F ;

FITZGERALD, GA .

THROMBOSIS RESEARCH, 1987, 47 (06) :647-656

[8] EFFECTS OF SYNVINOLIN ON PLATELET-AGGREGATION AND THROMBOXANE-B2 SYNTHESIS IN TYPE-IIA HYPERCHOLESTEROLEMIC PATIENTS [J].

DAVI, G ;

AVERNA, M ;

NOVO, S ;

BARBAGALLO, CM ;

MOGAVERO, A ;

NOTARBARTOLO, A ;

STRANO, A .

ATHEROSCLEROSIS, 1989, 79 (01) :79-83

[9]

FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499

[10] SERUM CHOLESTEROL, LIPOPROTEINS, AND RISK OF CORONARY HEART DISEASE - FRAMINGHAM STUDY [J].

KANNEL, WB ;

CASTELLI, WP ;

GORDON, T ;

MCNAMARA, PM .

ANNALS OF INTERNAL MEDICINE, 1971, 74 (01) :1-+

← 1 2 →